Sex disparities in melanoma: Beyond stage at diagnosis Authors: Eglė Janušonytė, Myrto Trakatelli Published: 2026 This exciting study by Lyngstrand et al. 1 provides population‐based evidence that men face a dual disadvantage in melanoma: more advanced disease at diagnosis and inferior stage‐specific prognosis. In a cohort of nearly 30,500 Danish patients, men more often presented with thicker, ulcerated tumours and were more likely to have nodal involvement or distant metastases at diagnosis compared with women. 1 To what extent are these disparities modifiable, and what should we do differently? The instinctive answer would be that observed disparities in stage at diagnosis reflect differences in healthcare‐seeking behaviour. Men consistently demonstrate lower rates of skin self‐examination and delayed presentation with suspicious lesions. 2 Anatomical distribution could explain that as melanomas in men occur more frequently on the trunk, areas less accessible to self‐detection compared to the lower extremity predominance seen in women. 3 However, if late presentation were the sole explanation, stage‐adjusted analyses would eliminate the sex disparity. They do not. In fact, the persistence of a 20–40% increased risk of recurrence and a 30–50% increased risk of melanoma‐specific mortality in men, as demonstrated in this study, points towards biological differences in tumour behaviour or host response. 1 This aligns with European cohort data showing females retain a survival advantage even after adjusting for thickness, ulceration and anatomical site. 4 The uncomfortable truth is that even if men presented as early as women, they would still fare worse. How do we explain this? Sex hormones may influence melanoma progression, and oestrogen receptor beta (ERβ) may have an anti‐proliferative role, as ERβ expression decreases with increasing Breslow thickness and is associated with more invasive disease. 5 However, the persistence of the female survival advantage when adjusted for proxy menopausal status (based on age at diagnosis) suggests that circulating oestrogen levels alone do not fully explain sex‐specific outcomes. 4 Moreover, the immune response seems to differ by sex, with female antigen‐presenting cells demonstrating greater efficiency and X chromosome‐linked immune genes potentially contributing to the difference of outcomes. 3 These findings carry practical implications and unmet needs for future investigations. Current AJCC staging and NCCN/ESMO guidelines do not incorporate sex into risk stratification. Whether surveillance protocols should incorporate sex‐specific follow‐up for men with localized disease merits a formal evaluation. From a research perspective, molecular characterization of tumours stratified by sex could show whether biological differences at the tumour level explain prognostic disparities, while trials evaluating sex‐tailored treatment strategies could determine whether outcomes can be equalized. This study is a reminder that sex disparities in melanoma are substantial and not fully explained by stage at presentation. Addressing these disparities will at the very least require a dual approach: improving early detection in men through targeted outreach while advancing our understanding of the biological underpinnings of sex‐specific tumour behaviour. FUNDING INFORMATION The authors have nothing to report. CONFLICT OF INTEREST STATEMENT EJ received support for attending meetings and/or travel from Jansen and LeoPharma and she is a JEADV Junior Editor and a TREAT subinvestigator. MT has received grants and contracts from Janssen, UCB and AbbVie; payment and honoraria from UCB, Genesis Pharma, Pierre Fabre Greece and EADV courses; support for attending meetings and/or travel from EADV, AbbVie, Pierre Fabre Greece and Genesis Pharma; she is Chair of the Advocacy Group at EADV. ETHICAL APPROVAL Not applicable. ETHICS STATEMENT Not applicable.